Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells

BACKGROUND: Tyrosine kinase inhibitor (TKI) resistance is a major obstacle in treatment of non-small cell lung cancer (NSCLC). MET amplification drives resistance to EGFR-TKIs in 5–20% of initially sensitive EGFR: mutated NSCLC patients, and combined treatment with EGFR-TKIs and MET-TKIs can overcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Clement, Michelle Simone, Gammelgaard, Kristine Raaby, Nielsen, Anders Lade, Sorensen, Boe Sandahl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653150/
https://www.ncbi.nlm.nih.gov/pubmed/33209611
http://dx.doi.org/10.21037/tlcr-20-522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653150/
https://www.ncbi.nlm.nih.gov/pubmed/33209611
http://dx.doi.org/10.21037/tlcr-20-522

Ejemplares similares